418Antimicrobial Profile of Enterobacteriaceae from North America from 2013
Bibliographic record
Abstract
Background. Enterobacteriaceae play an important role in the pathogenesis of hospital infections worldwide. The Tigecycline Evaluation Surveillance Trial (TEST) examines the susceptibility of pathogens isolated from multiple infectious processes from patients in geographically diverse populations. With the increase of antimicrobial resistance, continued surveillance and susceptibility testing of pathogens isolated from patients in North America is essential. The purpose of this report is to examine the susceptibility of selected Enterobacteriaceae species isolated from patients in the United States and Canada from 2013. Methods. 4,010* clinically significant Enterobacteriaceae sp. were obtained from patients with a wide spectrum of infections in patients in the United States and Canada. MICs were determined from 30 sites in 2013 using supplied broth microdilution panels. Susceptibility was interpreted according to CLSI guidelines. Results. The % susceptible for those 4,010 gram-negative bacilli against tigecycline and comparative antimicrobial agents is shown in the following table: AK=Amikacin, AC=Amoxicillin-Clavulanate, CPM=Cefepime, CFT=Ceftriaxone, LEVO=Levofloxacin, MER=Meropenem PT=Piperacillin-Tazobactam, TIG=Tigecycline *n's ≤ 15 are not reported Conclusion. In vitro tigecycline, meropenem and amikacin continue to be the most active antimicrobials against all Enterobacteriaceae. In the US and Canada the existence of levofloxacin resistant E. coli continues to be an issue. Additional monitoring of antimicrobial resistance in hospital pathogens in North America is warranted. Disclosures. B. Johnson, Pfizer: Independent Contractor, Consulting fee J. Johnson, Pfizer: Independent Contractor, Consulting fee S. Bouchillon, Pfizer: Independent Contractor, Consulting fee D. Hoban, Pfizer: Independent Contractor, Consulting fee M. Hackel, Pfizer: Independent Contractor, Consulting fee S. Lob, Pfizer: Independent Contractor, Consulting fee D. Biedenbach, Pfizer: Independent Contractor, Consulting fee H. Leister-Tebbe, Pfizer: Employee, Salary
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.002 | 0.003 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".